Cargando…

Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives

Detalles Bibliográficos
Autores principales:	Saeki, Sumito, Iwatani, Tsuguo, Kitano, Atsuko, Sakurai, Naomi, Tanabe, Yuko, Yamauchi, Chikako, Igarashi, Ataru, Kajimoto, Yusuke, Kuba, Sayaka, Hara, Fumikata, Sagara, Yasuaki, Ohno, Shinji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404164/ https://www.ncbi.nlm.nih.gov/pubmed/37395979 http://dx.doi.org/10.1007/s12282-023-01479-w

Ejemplares similares

Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives
por: Saeki, Sumito, et al.
Publicado: (2023)

Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)
por: Iwatani, Tsuguo, et al.
Publicado: (2021)

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020)

Surgical site infections in thyroid and parathyroid surgery in Japan: An analysis of the Japan Nosocomial Infections Surveillance database from 2013 to 2020
por: Iwatani, Tsuguo, et al.
Publicado: (2022)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

A Case of Brachial Lymph Node Recurrences after the Resection of Locally Advanced Breast Cancer
por: Onishi, Kayono, et al.
Publicado: (2022)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
por: Masuda, Norikazu, et al.
Publicado: (2018)

Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer
por: Iwatani, Tsuguo, et al.
Publicado: (2021)

Validation of the predictive accuracy of health-state utility values based on the Lloyd model for metastatic or recurrent breast cancer in Japan
por: Iwatani, Tsuguo, et al.
Publicado: (2021)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database
por: Kajimoto, Yusuke, et al.
Publicado: (2022)

Health-Related Quality of Life during COVID-19 Pandemic: Assessing Impacts of Job Loss and Financial Support Programs in Japan
por: Ikeda, Takaaki, et al.
Publicado: (2021)

Factors associated with treatment delay in women with primary breast cancer who were referred to reproductive specialists
por: Kitano, Atsuko, et al.
Publicado: (2019)

Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility
por: Kumegawa, Kohei, et al.
Publicado: (2023)

Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility
por: Kumegawa, Kohei, et al.
Publicado: (2023)

Current Status of Advance Care Planning and End‐of‐life Communication for Patients with Advanced and Metastatic Breast Cancer
por: Sagara, Yasuaki, et al.
Publicado: (2021)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor‐positive breast cancer: A single‐institute retrospective study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer
por: Kumegawa, Kohei, et al.
Publicado: (2022)

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study
por: Tanaka, Kiyo, et al.
Publicado: (2021)

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)
por: Ohtani, Shoichiro, et al.
Publicado: (2018)

Pneumatosis Intestinalis in Lung Cancer Induced Twice by Different Drugs: Bevacizumab and Pemetrexed
por: Nunomiya, Keiko, et al.
Publicado: (2021)

The path for medical associations to sponsor trustworthy guidelines: is it feasible?
por: Pagano, Domenico, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan
por: Igarashi, Ataru, et al.
Publicado: (2022)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Effects of Citric Acid and l-Carnitine on Physical Fatigue
por: Sugino, Tomohiro, et al.
Publicado: (2007)

Undifferentiated pleomorphic sarcoma in the anterior mediastinum with a rapidly progressive course: A case report
por: Sato, Masamichi, et al.
Publicado: (2020)

Clinicopathological Significance of TARBP2, APP, and ZNF395 in Breast Cancer
por: Oi, Ryoko, et al.
Publicado: (2016)

Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital
por: Kitano, Taito, et al.
Publicado: (2017)

Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy
por: Eguchi, Yuki, et al.
Publicado: (2022)

Oral nutrition for left‐sided malignant colonic obstruction after decompression with a transanal drainage tube: A case series of 6 patients
por: Kojima, Shigehiro, et al.
Publicado: (2018)

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2016)

Circulating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis
por: Nakamura, Kodai, et al.
Publicado: (2021)

Soluble (Pro)renin Receptor and Obstructive Sleep Apnea Syndrome: Oxidative Stress in Brain?
por: Takahashi, Kazuhiro, et al.
Publicado: (2017)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer
por: Fukada, Ippei, et al.
Publicado: (2022)

Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-γ stimulated macrophages
por: Yamauchi, Keiko, et al.
Publicado: (2009)

WTP for a QALY and health states: More money for severer health states?
por: Shiroiwa, Takeru, et al.
Publicado: (2013)

A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v8vghnpksbhgnba82469phngn5